Compare SPDR Gold Trust (GLD) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Incyte Corporation — how do they compare? SPDR Gold Trust trades at $384.58 (market cap $139.66B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: SPDR Gold Trust is far larger — about 6.1× Incyte Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, SPDR Gold Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Incyte Corporation for 33 Days on average.
| GLD | INCY | |
|---|---|---|
Market Cap | $139.66B | $22.85B |
Volume | 9,544,773 | 1,927,029 |
52-Week High | $495.90 | $129.93 |
52-Week Low | $362.32 | $83.80 |
Typical Hold Time | 74 Days | 33 Days |
Sector | — | Health |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD trades at $378.67, up 0.74% with bearish technical signals dominating as 17 indicators signal sell versus 2 buy signals. The stock faces resistance at $380-$384 while finding support at $377-$373. Recent news highlights pressure from rising Treasury yields and dollar strength overwhelming safe-haven demand, with gold failing to sustain gains despite weak employment data.
The outlook remains cautious with technical indicators signaling bearish momentum and fundamental data unavailable. Key risks include persistent rate hike expectations and dollar strength, though some analysts see tactical buying opportunities. Investors should monitor Fed policy decisions and inflation trends for directional catalysts.
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
